Every 10-Q that Annovis Bio, Inc. (ANVS) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow ANVS and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full ANVS filings page.
Annovis Bio, Inc. is a late-stage clinical biopharmaceutical company developing its lead candidate buntanetap for Alzheimer’s and Parkinson’s disease. It reported a six-month net loss of $32.4 million, driven mainly by research and development expenses of $28.7 million as it advances a fully enrolled pivotal Phase 3 Alzheimer’s trial with 860 early AD patients and an open-label extension study in Parkinson’s disease.
Cash and cash equivalents were $18.7 million at June 30, 2026, while accumulated deficit reached $196.1 million. Management states that existing cash is expected to fund operations only into the fourth quarter of 2026 and concludes that substantial doubt exists about the company’s ability to continue as a going concern. To fund operations, Annovis raised equity during the period, increasing shares outstanding to 42.6 million and recognizing a warrant liability of $19.9 million from new liability-classified Canaccord warrants.
Annovis Bio, Inc. reported a sharp increase in spending as it advances late-stage neurology programs and highlighted serious liquidity risk. For the quarter ended March 31, 2026, the company posted a net loss of $17.6 million, compared with $5.5 million a year earlier, driven mainly by higher research and development costs of $16.7 million as its pivotal Phase 3 Alzheimer’s trial and Parkinson’s open-label extension ramped up.
Cash and cash equivalents fell to $14.2 million from $19.5 million at year-end, with operating activities using $9.0 million of cash in the quarter. Management concluded there is substantial doubt about the company’s ability to continue as a going concern, noting existing cash is not sufficient for 12 months after the report date despite recent financings. Subsequent to quarter-end, Annovis raised additional capital, including a $10.0 million gross underwritten unit offering and further at-the-market share sales, but still anticipates ongoing losses as development of lead candidate buntanetap continues.
Annovis Bio (ANVS) filed its Q3 2025 10‑Q reporting continued operating losses and a going‑concern warning. The company posted a Q3 net loss of $7.3 million as research and development rose to $6.3 million with spending tied to its 6‑month Alzheimer’s trial and a Parkinson’s open‑label extension. General and administrative costs fell to $1.1 million. Cash and cash equivalents were $15.3 million, and warrant liability measured at fair value was $299,000.
Year‑to‑date, the net loss was $19.0 million, with higher interest income reflecting cash raised earlier in the year. Management concluded that existing cash is not sufficient for the period through one year after this report, indicating substantial doubt about the company’s ability to continue as a going concern, and plans to seek additional capital.
Financing activity included a February 2025 underwritten offering of 5.3 million units at $4.00 per unit (net proceeds $19.3 million) and sales under an ATM program. Subsequent to quarter‑end, the company raised $5.5 million in a registered direct offering on October 10, 2025 and $3.1 million on October 26, 2025. Shares outstanding were 20,187,904 at September 30, 2025; as of November 12, 2025, outstanding shares were 26,502,889.
Annovis Bio reported a cash balance of $17.1 million as of June 30, 2025 and a six-month net loss of $11.8 million, leaving an accumulated deficit of $146.6 million. Operating loss for the six months was $12.6 million versus $15.6 million in the prior year period. Net proceeds of $19.3 million were generated from a February 2025 underwritten offering with ThinkEquity, and the company sold an additional $0.5 million of common stock under its December 2024 ATM during the six months.
The filing discloses that management has concluded substantial doubt exists about the company’s ability to continue as a going concern and is pursuing additional capital through equity or debt financings, collaborations or cost deferrals. On the clinical front, Annovis initiated its FDA-cleared pivotal ANVS-25001 Phase 3 trial in early Alzheimer’s disease in February 2025 and describes prior topline PD and AD data and alignment with the FDA on a development path for buntanetap.